For the fourth quarter of 2025, Immunome reported no collaboration revenue and a net loss of 41577000. Research and development expenses remained elevated as the company advanced its oncology pipeline. Adjusted EPS for the quarter was -0.75.

Immunome, Inc. reported a net loss of $41.64 million for the three months ended March 31, 2025, an improvement from the $129.492 million net loss in the same period last year. Collaboration revenue increased to $2.926 million, up from $1.029 million year-over-year, primarily due to increased research and development activities allocated to AbbVie. Operating expenses significantly decreased due to the absence of in-process research and development expenses, which were substantial in the prior year.

Immunome reported a net loss of $292.963 million for the full year ended December 31, 2024. The company's cash, cash equivalents, and marketable securities totaled $217.3 million as of December 31, 2024, and its cash runway is expected to extend into 2027. Key pipeline updates include topline data for the Phase 3 RINGSIDE study of varegacestat expected in the second half of 2025, the first patient dosed in the Phase 1 clinical trial for IM-1021, and an IND submission for IM-3050.

Immunome announced its third quarter 2024 financial results, highlighting the advancement of its pipeline with topline data for the RINGSIDE Part B trial of AL102 expected in the second half of 2025, and IND submissions for IM-1021 and IM-3050 on track.

Immunome reported its financial results for the second quarter ended June 30, 2024. The company is focused on advancing its pipeline of oncology therapies and preparing AL102 for regulatory submissions. IND submissions for IM-1021 and IM-3050 are expected in the first quarter of 2025.

Immunome reported its Q1 2024 financial results, highlighting the completion of AL102 integration and progress in regulatory submissions. The company is also advancing IM-1021 and IM-3050 towards clinical trials and focusing on developing next-generation ADC technology.

Immunome reported its full-year 2023 financial results, highlighting a transformative year marked by the merger with Morphimmune, pipeline advancement, and leadership expansion. The company is focused on developing its existing assets and expanding the pipeline with novel ADCs and RLTs.

Immunome reported its Q3 2023 financial results, highlighting the transformative merger with Morphimmune and a concurrent $125 million private placement. The company is focused on developing targeted cancer therapies with a strong balance sheet and technology platform.

Immunome reported its financial results for the second quarter ended June 30, 2023, and provided a corporate update, highlighting the potential synergy between Morphimmune’s Targeted Effector Platform and Immunome’s Discovery Engine following the anticipated merger completion by the end of the year.

Immunome reported its Q1 2023 financial results, highlighting the external validation of its Discovery Engine through the collaboration with AbbVie and the formation of an Antibody-Drug Conjugate and T Cell Redirection Advisory Board.

Immunome reported financial results for the fourth quarter ended December 31, 2022, and provided a corporate update, highlighting their strategic collaboration with AbbVie.

Immunome reported its Q3 2022 financial results and provided a corporate update, focusing on the clinical trial for IMM-BCP-01 and the expansion of its oncology portfolio.

Immunome reported its Q2 2022 financial results, highlighting its transition into a clinical-stage company with the ongoing Phase 1b study of IMM-BCP-01 and continued progress with its lead oncology candidate, IMM-ONC-01.

Immunome reported on its progress with IMM-BCP-01 for COVID-19 treatment, which received FDA clearance for a Phase 1b clinical trial, and IMM-ONC-01, an antibody treatment targeting IL-38, with an IND submission targeted for the second half of 2022.

Immunome reported its financial results for the fourth quarter ended December 31, 2021, highlighting the FDA's safe-to-proceed notification for IMM-BCP-01 and the continued progress of IMM-ONC-01 towards an IND submission.

Immunome reported its Q1 2021 financial results, highlighting progress in its product pipeline, including IMM-BCP-01 and IMM-ONC-01. The company also appointed Dennis Giesing, Ph.D. as Chief Development Officer and Corleen Roche as Chief Financial Officer and raised $27 million in gross proceeds in a private placement.

Immunome reported its Q4 and full year 2020 financial results, highlighting a transformational period marked by a successful NASDAQ IPO that raised $44.9 million in gross proceeds. The company is advancing its IMM-ONC-01 program into IND-enabling studies and expects to provide development program updates in the second quarter of 2021.

Immunome reported a net loss of $8.4 million, or $7.52 per share, for the quarter ended September 30, 2020. The company completed an IPO in October, resulting in net proceeds of $41.7 million.